Repositorio Digital de la UPF
Publicación
Artículo científico (JournalArticle)
Self-reported sleep quality and longitudinal amyloid burden in clinically unimpaired adults from the AMYPAD PNHS study
Background: Poor self-reported sleep quality is associated with cognitive impairment. Alzheimer's disease (AD) patients present sleep disruptions decades before they start to decline clinically. Similarly, amyloid-ß (Aß) starts accumulating during the preclinical phase of the disease. This study investigated associations between self-reported sleep quality and Aß burden longitudinally in clinically unimpaired (CU) adults. Methods: Four hundred seventeen CU adults from the AMYPAD PNHS cohort were included, with baseline self-reported sleep quality assessments (Pittsburgh Sleep Quality Index, PSQI) and longitudinal Aß PET scans. Participants were categorized by baseline Aß levels as negative (A-), grey-zone (GZ), or positive (A+). Linear mixed-effects (LME) models tested the association between baseline sleep quality and Aß burden over time, including interaction effects with baseline Aß status. Results: Global PSQI score was not associated with Aß burden over time in the entire group. However, a significant interaction with baseline Aß status was found, whereby poorer subjective sleep quality was linked to accelerated Aß accumulation in GZ participants. Conclusions: Poorer subjective sleep quality is associated with faster Aß accumulation in CU individuals with intermediate Aß levels, highlighting sleep as a potential target for early AD prevention and identifying an optimal intervention window., OG-R received support from the grant IJC2020-043417-I, funded by MCIN/AEI/https://doi.org/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; this study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116", co-funded by the European Union/FEDER, and through the project "CB16/10/00417" (OG-R). GS-B receives support from the grant CP23/00039 (Miguel Servet), funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE +, and receives funding from the MCIN/AEI/https://doi.org/10.13039/501100011033 through the project PID2020-119556RA-I00 and through the project PID2024-163071OB-I00, funded by MICIU/AEI/https://doi.org/10.13039/501100011033 and by the European Union FEDER. This work used data from AMYPAD PNHS that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking received support from the European Union’s Horizon 2020 research and innovation program and EFPIA. This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. The FACEHBI study was supported with funds from Ace Alzheimer Center Barcelona, Life Molecular Imaging, Grifols, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne, and IrsiCaixa. The FACEHBI study was part of the AMYPAD-PNHS project, which received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. MB received funding support from CIBERNED (Instituto de Salud Carlos III (ISCIII); EU/EFPIA Innovative Medicines Initiative Joint Undertaking, ADAPTED Grant No. 115975; EXIT project, EU Euronanomed3 Program JCT2017 Grant No. AC17/00100; MOPEAD, Innovative Medicine Initiative, Grant. Nº. 115,985; PreDADQoL, ERA-NET (call 2015). Grant nº AC15/00082; TARTAGLIA (Red federada para acelerar la aplicación de la inteligencia artificial en el sistema sanitario español); PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) Grant No. AC19/00097; GECONEU Grant No. 2023–1-ELO1-KAZZ0-HED-000032173 co –founded by the European Union; Grants PI13/02434, PI16/01861, BA19/00020, and PI19/01301 from the Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by Instituto de Salud Carlos III (ISCIII)- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER – “Una manera de Hacer Europa”); Fundació “La Caixa” and Grífols (GR@ACE project); and Proyectos de Investigación de Medicina Personalizada (ISCIII), PMP-DEGESCO, Grant Nº PMP22/00022. MM has received funding support from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 796706, and the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—Una manera de hacer Europa) grant PI19/00335.